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Abstract
DNA hypomethylation is an important epigenetic modification found to occur in many different cancer types, leading to the
upregulation of previously silenced genes and loss of genomic stability. We previously demonstrated that hypoxia and
hypoglycaemia (ischemia), two common micro-environmental changes in solid tumours, decrease DNA methylation
through the downregulation of DNMTs in human colorectal cancer cells. Here, we utilized a genome-wide cross-platform
approach to identify genes hypomethylated and upregulated by ischemia. Following exposure to hypoxia or
hypoglycaemia, methylated DNA from human colorectal cancer cells (HCT116) was immunoprecipitated and analysed
with an Affymetrix promoter array. Additionally, RNA was isolated and analysed in parallel with an Affymetrix expression
array. Ingenuity pathway analysis software revealed that a significant proportion of the genes hypomethylated and
upregulated were involved in cellular movement, including PLAUR and CYR61. A Matrigel invasion assay revealed that
indeed HCT116 cells grown in hypoxic or hypoglycaemic conditions have increased mobility capabilities. Confirmation of
upregulated expression of cellular movement genes was performed with qPCR. The correlation between ischemia and
metastasis is well established in cancer progression, but the molecular mechanisms responsible for this common
observation have not been clearly identified. Our novel data suggests that hypoxia and hypoglycaemia may be driving
changes in DNA methylation through downregulation of DNMTs. This is the first report to our knowledge that provides an
explanation for the increased metastatic potential seen in ischemic cells; i.e. that ischemia could be driving DNA
hypomethylation and increasing expression of cellular movement genes.
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the ECM [5]. Through stabilization of a subunit of the hypoxiaresponsive transcription factor, HIF1a, hypoxia drives expression
of these two genes, and many others, promoting metastasis. Cells
may also be rendered more motile via epigenetic reprogramming.
Several relevant genes such as uPA [6] and S100A4 [7] have
altered epigenetic patterning in cancer cells, allowing cell
morphology to be modified to a more metastatic-favourable state.
What remains unknown is if epigenetic modifications and ischemia
are linked in promoting tumour metastasis.
DNA methylation is an important epigenetic mechanism which
regulates gene expression [8]. Methylated DNA is associated with
transcriptional silencing, since the methyl groups at cytosine
residues change the configuration of DNA and therefore prevent
transcription factors from binding [9], as well as triggering the
recruitment of repressors and chromatin modifying enzymes that
further silence expression through chromatin condensation
[10,11]. Several DNA methyltransferases (DNMT) catalyze the
conversion of cytosine to 5-methylcytosine [12], with the most
commonly studied DNMTs being DNMT1 (a maintenance
methyltransferase) and DNMT3a and DNMT3b (de novo
methyltransferases) [13].

Introduction
Solid tumours undergo a fundamental process known as
angiogenesis (recruitment of neo-vasculature) in order to maintain
adequate levels of oxygen and nutrients to the expanding mass [1].
Tumour blood vessels are highly abnormal and due to the rate of
tumour growth which exceeds the rate of angiogenesis, areas of a
tumour will develop reduced blood flow, or ischemia [2]. In
addition to other changes, ischemic regions will have areas of
hypoxia and hypoglycaemia, and while the impact of hypoglycaemia on tumorigenesis is not well studied, the role of hypoxia in
cancer progression is well documented and includes increasing
genetic instability, and stimulating cell invasion and angiogenesis,
thereby contributing to metastasis [3].
Cellular movement/migration is a critical step in metastasis,
which is the cause of most cancer-related mortalities [4]. A variety
of molecular changes can cause a cell to be motile and travel into
the lymphatic or vasculature system, eventually leading to arrest at
a new site in the body [5]. Cells within an ischemic environment
have a higher metastatic potential through the upregulation of
genes such as VEGF to stimulate angiogenesis, and urokinase
plasminogen activator (uPA) which activates plasmin to degrade
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and 17q that displayed regional chromosomal gains (indicated in
red), as previously reported by others [30]. Very few complete loss
of copies were seen (blue), except for the Y chromosome which has
been reported to be absent in 50–100% of HCT116 cells [31].
Thus, in comparison with other cancer cell lines, HCT116 have a
relatively normal and stable karyotype with minimal chromosomal
instability [30].

In cancer, two common disruptions to DNA methylation
patterns are observed: promoter-specific hypermethylation and
global hypomethylation [14]. Most studies have focused on DNA
hypermethylation and the impact that silencing tumour suppressor
genes has on tumour initiation, progression, and prognosis. DNA
hypomethylation on the other hand has been overshadowed by the
extensive attention to DNA hypermethylation in cancer therapy,
even though hypomethylation was the first epigenetic disruption
noted in cancer [15,16]. Despite the initial lack of understanding
regarding the importance of DNA hypomethylation in cancer, it is
now known that repetitive sequences become demethylated and
lead to genomic chaos [17,18]. As with DNA hypermethylation,
hypomethylation can be site-specific, thereby contributing to
enhanced expression [16]. In addition to such gene-specific effects,
genomic instability, loss of imprinting [19] and abnormal Xchromosome activation also contribute to tumorigenesis [20].
Hoffmann and Schultz [16] hypothesized that DNA hypomethylation accelerates the adaptation of cancer cells to the
dynamic microenvironment through selection for particular gene
functions, such as motility. Evidence for this theory lies in the
urokinase plasminogen activator (uPA) gene. A serine protease
involved in degradation of the extracellular matrix, uPA has been
shown to have a hypomethylated promoter region, leading to
over-expression in both breast and prostate cancer and is directly
associated with increased invasive and metastatic potential [6].
Melanoma-associated antigen (MAGE) is another of the group of
genes found to be demethylated and upregulated in many cancers
like melanoma, colorectal, gastric, and non-small cell lung cancer
[21,22,23,24,25]. Overall, multiple mechanisms may be responsible for the dysregulation of DNA methylation in cancer.
Overexpression of DNMTs has been reported in many different
cancers [26] and explains aberrant hypermethylation, but less
focus has gone into understanding DNA hypomethylation, even
though DNA hypomethylation plays an equally important role in
modifying the cancer epigenome.
Our previous work described a novel relationship between
ischemia and DNA methylation, with reduced methyl cytosine
seen in cells from ischemic regions of tumours [27]. We also found
that in HCT116 human colorectal cancer cells, DNMT1,
DNMT3a, and DNMT3b expression and activities were reduced
by in vitro hypoxia and hypoglycaemia [28]. These changes in
expression and activity were concurrent with hypomethylation of
the p16INK4a promoter region in hypoglycaemic conditions [28].
In the present study, we explored the expression and methylation
changes in HCT116 cells on a genome-wide level, utilizing a crossplatform approach to identify genes regulated by ischemic
conditions. Given our previous findings, combined with the
common observation of increased metastatic potential in ischemic
tumours, we hypothesized that increased cellular motility of
human colorectal cancer cells in ischemic conditions is due to the
upregulation of motility-associated genes, and that these changes
in expression are driven by ischemia-mediated DNA hypomethylation.

Hypoglycaemia impacts more genes than hypoxia
Expression analysis was performed to quantitatively evaluate
gene expression changes in HCT116 cells under ischemic
conditions. The expression arrays indicated that following
exposure to hypoxia for 48 hours, HCT116 cells had 310 and
1081 genes up- and down-regulated, respectively. When cells were
exposed to hypoglycaemia, 1052 and 2433 genes were up- and
down-regulated, respectively (Table 1). Analysis of promoter
methylation using Affymetrix 1.0R tiling array revealed that
hypoxia resulted in 1386 hypomethylated genes, and 1655
hypermethylated genes. Growth in hypoglycaemic conditions
resulted in 1940 hypomethylated genes, and 1980 hypermethylated genes (Table 1). Thus, both expression and promoter
methylation patterns were most heavily impacted by hypoglycaemia, as measured by total number of significantly changed genes.

Cross-platform analysis
Next, we assessed the functional significance of these complex
gene expression and epigenetic (DNA methylation) profiles. Using
the Partek Software Suite, unique genes that were hypomethylated
and upregulated (as well as hypermethylated and downregulated)
were overlaid in order to identify changes in gene expression
associated with changes in promoter methylation. There were 58
unique genes hypermethylated and downregulated by hypoxic
conditions, and 161 genes by hypoglycaemia (Data not shown).
We focused on the genes that were hypomethylated and increased
in expression, since our previous work showed DNMTs were
repressed in ischemia. We observed that 18 and 96 unique genes
were hypomethylated and upregulated by hypoxia and hypoglycaemia, respectively (Figure 2). Partial lists of these genes can be
seen in Tables 2 and 3, with the complete list presented in Table I
in Information S1.

Ingenuity Pathway Analysis of hypomethylated and
upregulated genes
Ingenuity Pathway Analysis (IPA) was used to analyze and
classify the hypomethylated and upregulated genes into functional
pathways, in order to better understand the biological relevance of
the genes from our data set. The software determines if a
biological function is enriched for in a data set by examining the
whole gene list for functional annotations found in the ingenuity
knowledge base, and performing a Fisher’s exact test comparing
the ratio of genes with a given annotation in the data set against
the ratio of genes having that same annotation in the whole
population (i.e. all the genes on the HG U133 Plus 2.0 array). If
the first ratio is significantly higher than the second, then the list is
said to be enriched for genes having that annotation.
With hypoxia exposure, the top three cellular functions from
our list of hypomethylated/upregulated genes were: cell-to-cell
signaling, cellular movement, and connective tissue development
(Figure 3). Hypoglycaemia enriched for changes in cell death, cell
cycle, and regulation of gene expression (Figure 4). Although not
within the top few functional categories, cellular movement was
also an enriched function in the hypoglycaemic group. Network
analysis was also performed to provide a graphical representation

Results
Minimal copy number variation
The copy number of genes in the HCT116 cells was assessed
with the Affymetrix SNP 6.0 array to determine if, and to what
extent, the cells we used had drifted/mutated in culture compared
to the original karyotype of this cell line. When compared to a
pooled normal human karyotype from the International HapMap
project database [29], the cells lacked extensive chromosomal
abnormalities (Figure 1). We did observe regions on 8q, 10q, 16q,
PLOS ONE | www.plosone.org
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Figure 1. SNP 6.0 array of HCT116 cells to visualize copy number variation. Numbers (and X/Y) correspond to chromosomes, and MT
represents mitochondrial DNA. Results were compared to a dataset from Affymetrix containing 270 mixed population samples from the International
HapMap Project [29]. Regions in grey indicate no change in copy number, red indicates a copy number gain, and blue a copy number loss. This array
was performed in duplicate.
doi:10.1371/journal.pone.0103243.g001
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Table 1. Summary of expression and promoter methylation arrays.

Hypoxia

Hyperglycaemia

Array Type

Change

Number of genes

Change

Number of genes

Expression

Upregulated

310

Upregulated

1052

Downregulated

1081

Downregulated

2433

Promoter Methylation

Hypomethylated

1386

Hypomethylated

1940

Hypermethylated

1655

Hypermethylated

1980

Total number of significantly changed genes in both expression (p,0.05) and promoter methylation (p,0.01) arrays, by hypoxia (A) or hypoglycaemia (B), compared to
control.
doi:10.1371/journal.pone.0103243.t001

lated in hypoxia, compared to control conditions (Figure 6A). The
fold-changes in expression of these two genes as determined by
qRT-PCR were comparable to the fold-change seen in the
expression array (Table 2). Genes assessed for expression changes
by qRT-PCR in hypoglycaemic conditions included EPHA2,
NRAS, NEDD4L, and CYR61. All four of these genes were
upregulated in the expression array analysis and hypomethylated
in the promoter tiling array, except EPHA2 was not hypomethylated according to the promoter array. Significant upregulation of
EPHA2, NEDD4L and CYR61 in hypoglycaemia was confirmed
by qRT-PCR (Figure 6B).

of known biological relationships of the hypomethylated and
upregulated genes. The networks are generated by determining a
focus molecule, and then examining the gene lists for the most
connections to the focus molecule, based upon the literature in
Ingenuity’s database. The top networks (having the most
connections) for both hypoxia and hypoglycaemia involved genes
which have roles in cellular movement. In hypoxic conditions,
PLAUR, LDLR, and LAMB3 (Figure 5A) were all in one network
and have all been shown to be involved in cellular movement. The
top network in hypoglycaemic conditions included cellular
movement genes ETS1, KLF4, IL6ST, NEDD4L, and NRAS
(Figure 5B). It is important to note that some genes in our list may
have biological functions/annotations that the Ingenuity database
does not recognize. As an example, AFAP1L1 was not in the
Ingenuity list of genes involved in cellular movement, however
there is evidence for this molecule’s role in migration and invasion
[32]. Based on the IPA analysis of functional pathways and
networks, the category ‘‘cellular movement’’ appeared interesting
and relevant and we further pursued the genes associated with
these functions for array validation.

Ischemic-conditions enhance HCT116 motility
Invasion assays were performed to determine the effects of
ischemia on cell motility. After 48 hours in ischemic conditions, it
was evident that cells exposed to hypoxia and hypoglycaemia had
significantly increased mobility and invasive capabilities as
determined by the ability of cells to degrade and migrate through
Matrigel (Figure 7). This functional assay supported our finding
that elevated expression of mobility-associated genes via promoter
hypomethylation in ischemic conditions translates to phenotypic
changes in HCT116 cells.

Migration-associated genes are enriched in hypoxia and
hypoglycaemia

Discussion

The cross-platform analysis of genes hypomethylated and
upregulated by hypoxia and hypoglycaemia revealed a number
of genes that are involved in cellular movement: LDLR, LAMB3,
ALDOA, PLAUR, SCAI, and NEDD4L in the hypoxic group
(Figure 3), and ITGB1, ETS1, IL6ST, NRAS, TJP1, SMAD3,
TMOD3, LATS2, KLF4, ADI1, NCOA3, PTEN, CSNK2A2,
TRIO, CSNK2A1, BRD4, RTN4, SEMA3C, NEDD4L, CYR61,
TFPI, and HEY1 in the hypoglycaemic group (Figure 4). In
addition to these genes, we observed two others that were
hypomethylated and upregulated likely also involved in cellular
movement. ANKRD37 and AFAP1L1 in the ‘hypoxic group’
have been shown to be involved in migration and invasion of
cancer cells (Table 2). Many of the ‘‘cellular movement’’ genes in
our analysis are involved in mediating cellular attachment, either
to other cells or the ECM, or in ECM degradation, all processes
required for a cell to move within tissue and to enter blood vessels.

In this study, we utilized a cross-platform approach of
identifying genome-wide changes in promoter methylation and
gene expression to discover how acute ischemia impacts methylation-mediated gene expression in human colorectal cancer cells.
We identified and verified that genes involved in enhancing
cellular movement are regulated under ischemic conditions,
represented by hypoxia and hypoglycaemia in vitro.
Acute ischemia frequently occurs in solid tumours due to the
dynamic tumour vasculature and the rapid expansion of tumours
exceeding angiogenesis [2]. We previously established that acute
ischemia leads to down-regulation of both cellular methylcytosine
content and DNMT expression and activity [27,28]. To pursue
this finding and identify which genes are hypomethylated and
upregulated by ischemia on a global scale, we used platforms that
share the common Affymetrix technology base to facilitate crossreferencing of data sets. We thus used a single software
bioinformatics package (Partek Genomic Suite) to import, analyze
and correlate raw data from the various microarray platforms
[33]. From our genome-wide, cross-platform study, we found
ischemic conditions significantly upregulated genes involved in cell
motility and invasion, and these genes had demethylated promoter
regions identified by the arrays. Hence, our cross-platform
analyses point to a set of genes that appear responsive to

Confirmation of increased expression of cellular
movement genes
We used qRT-PCR to quantify expression of selected genes
from both the hypoxia and hypoglycaemia groups. We choose to
focus on genes involved in cellular movement identified in the
cross-platform analysis as upregulated and hypomethylated. For
the hypoxia group, we examined PLAUR, AFAP1L1, and
LAMB3. Both PLAUR and LAMB3 were significantly upreguPLOS ONE | www.plosone.org
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Figure 2. Venn diagram of significantly changed unique genes from cross-platform analysis. Number of genes which were both
significantly hypomethylated and upregulated by hypoxia (A) and hypoglycaemia (B) are indicated in the overlapped regions.
doi:10.1371/journal.pone.0103243.g002

and increased binding of HIF1 [7]. These studies provide
supporting evidence towards the concept that hypomethylation is
required in hypoxic conditions for gene expression to occur.
A relevant gene significantly upregulated and hypomethylated
by hypoxia from our cross-platform analysis is plasminogen
activator urokinase receptor, or PLAUR, the receptor for
urokinase type plasminogen activator (uPA). uPA is a serine
protease that catalyzes conversion of plasminogen to plasmin,
which then degrades the ECM [35]. PLAUR is involved in cellular
movement and metastasis [36] and expression increases during the
critical transition from severe dysplastic adenoma to invasive

environmental hypoxia and hypoglycaemia via altered CpG
methylation.
Previous studies have demonstrated that some HIF1-mediated
genes (e.g. CA9, EPO) require the CpG within the hypoxia
response element (HRE) to be demethylated in order for HIF1 to
bind, and expression to occur [34–36]. S100A4, a member of the
S100 family of Ca2+-binding proteins, is known to be involved in
cancer cell motility by its ability to activate non-muscle myosin,
and has been shown to be related to gastric cancer progression
[34]. S100A4 was upregulated by hypoxia in ovarian cancer, with
reduced methylation of the HRE in S100A4’s promoter regions

PLOS ONE | www.plosone.org
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Table 2. List of genes that were both hypomethylated and upregulated by hypoxia.

Expression

Promoter Methylation

Gene Symbol

p-value

Fold-Change

p-value

MAT score

ANKRD37

0.0003

25.14

0.008

23.85

TMEM158

0.0022

13.21

0.007

23.97

DDIT4

0.0001

8.51

0.010

23.71

ALDOA

0.0050

5.26

0.010

23.74

KDM3A

0.0031

5.01

0.009

23.75

LDLR

0.0427

3.13

0.005

24.24

SEMA4B

0.0006

2.91

0.009

23.82

SPRY1

0.0260

2.90

0.009

23.83

RBPJ

0.0061

2.81

0.007

23.93

UFM1

0.0159

2.60

0.006

24.03

PLAUR

0.0011

2.58

0.010

23.72

LAMB3

0.0171

2.50

0.009

23.76

NEDD4L

0.0004

2.45

0.007

23.94

SCAI

0.0261

2.35

0.007

24.00

PFKP

0.0025

2.27

0.009

23.78

RYBP

0.0091

2.13

0.004

24.34

CUL4B

0.0077

2.13

0.007

23.92

AFAP1L1

0.0306

2.07

0.006

24.12

Partek software was used to overlay the significant gene lists from the promoter methylation and expression arrays (the 18 genes from Figure 2A).
doi:10.1371/journal.pone.0103243.t002

Cysteine-rich 61 (CYR61) is a member of the CCN family of
growth factors. CYR61 is known to link cell surface and the ECM, and
is involved in cell adhesion, proliferation and migration [47]. We have
identified CYR61 as a hypoglycaemia-responsive gene. CYR61
expression is increased in a variety of cancers including breast,
melanoma, glioma, gastric, colon, bladder, prostate, and pancreas
[47]. Silencing of CYR61 in osteosarcoma and esophageal squamous
carcinoma cells led to reduced migration and cell invasion [48,49].
CYR61 expression has been shown to correlate with the aggressiveness of pancreatic cancer cells, further demonstrating the role of this
growth factor in metastasis [47]. To date, there are no studies showing
that CYR61 expression is regulated by promoter methylation.
However, CYR61 expression is regulated by the transcription factor
STAT3 [50], and others have demonstrated that the CpG in the
STAT3 binding site requires demethylation for STAT3 to bind and
express its target genes [51].
Two other genes that were upregulated in our analysis by
hypoglycaemia were EPHA2 and NEDD4L. EPHA2 is a transmembrane receptor tyrosine kinase, which is overexpressed in many
carcinomas, including early stage colorectal cancer [52], and its
expression is highly correlated to tumour invasion and metastasis
[53]. NEDD4L is an E3 ubiquitin-ligase shown to have increased
expression with gallbladder cancer progression. Using siRNA,
silencing of NEDD4L led to decreased Matrigel and collagen
invasion of gallbladder cancer cells, and its role in invasion is possibly
due to its association with MMPs [54]. Presently, there are no studies
demonstrating that promoter demethylation could be responsible for
upregulation of either of these two genes.
Melanoma-associated antigens (MAGEs) are a group of genes
whose expression is silenced in most normal somatic tissue, except
in the testis, but upregulated in many cancers [22]. One study
showed that the promoter region of MAGE-A1 contains two ETS
binding sites which must be demethylated for the transcription

carcinoma in colorectal cancer [35]. Additionally, PLAUR is
upregulated in hypoxia [37] through HIF1 activity [38], and is
responsible for hypoxia-mediated invasiveness in HCT116 cells
[39]. As well, the ligand uPA is regulated by the transcription
factor ETS1, and the binding sites for ETS1 in the uPA promoter
must also be demethylated for transcription to occur [40].
Laminin beta 3 (LAMB3), a subunit of laminin-5 (laminin-332),
is a basement membrane protein thought to mediate cell
attachment, migration, and organization of cells during embryonic
development. LAMB3 expression is higher in malignant esophageal squamous cell carcinoma than in normal tissue, and
expression correlates with depth of invasion and survival [41].
LAMB3 has also been reported to be hypomethylated and
upregulated in gastric cancer [42]. We confirmed that LAMB3
was upregulated in hypoxic conditions in CRC. Interestingly, one
study examined colon adenocarcinoma biopsies, and saw laminin5 positive staining was associated with budding cancer cells located
at the tip of invading malignant epithelium, and that laminin-5
colocalized with PLAUR [43].
In addition to PLAUR and LAMB3, S100A10 was another
gene upregulated by both hypoxia and hypoglycaemia based on
our array analysis, and has been shown to be important in cancer
cell invasion and metastasis through colocalization with uPA/
PLAUR system [44]. S100A10 is overexpressed in gastric cancer
[45] and is essential for tumour-associated macrophage migration
into tumour sites [46]. We are the first to report that PLAUR and
LAMB3 appear to be key gene targets in ischemia-mediated
hypomethylation, similar to S100A4. PLAUR, LAMB3 and
S100A10 could be working in conjunction with each other to
increase cellular mobility in hypoxic tumours. Further studies are
needed to determine if these proteins are colocalized in hypoxic
tissue.
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Table 3. List of the top 30 genes that were both hypomethylated and upregulated by hypoglycaemia.

Expression

Promoter Methylation

Gene Symbol

p-value

Fold-Change

p-value

CYR61

0.0000

31.35

0.009

MAT score
23.85

ETS1

0.0005

30.72

0.010

23.77

KLF4

0.0002

22.29

0.009

23.85

ELL2

0.0001

11.06

0.002

25.10

NEDD4L

0.0001

11.03

0.002

25.05

LATS2

0.0000

9.27

0.006

24.13

SGMS1

0.0004

8.28

0.002

25.29

INTS6

0.0008

8.22

0.007

23.97

HEY1

0.0002

8.18

0.009

23.82

COL12A1

0.0012

6.87

0.006

24.14

PHIP

0.0006

5.61

0.009

23.83

ARHGEF12

0.0003

5.54

0.004

24.55

EPC1

0.0002

5.47

0.006

24.12

SETX

0.0009

5.42

0.003

24.64

C16orf52

0.0003

5.10

0.008

23.93

PRDM10

0.0012

4.97

0.006

24.15

DCAF10

0.0001

4.88

0.008

23.94

NAB1

0.0021

4.80

0.003

24.62

RYBP

0.0009

4.53

0.004

24.40

TMOD3

0.0017

4.27

0.003

24.58

TJP1

0.0013

4.23

0.009

23.82

UBQLN1

0.0020

4.19

0.008

23.95

OSBPL3

0.0001

4.12

0.005

24.32

NRAS

0.0030

4.04

0.009

23.83

GPR87

0.0000

3.91

0.009

23.79

ESYT2

0.0002

3.68

0.010

23.77

KLF3

0.0004

3.62

0.009

23.79

SOCS5

0.0002

3.61

0.009

23.83

GPBP1

0.0009

3.61

0.008

23.94

SLC38A1

0.0006

3.55

0.004

24.44

Partek software was used to overlay the significant gene lists from the promoter methylation and expression arrays (the 96 genes from Figure 2B).
doi:10.1371/journal.pone.0103243.t003

factor to bind and expression to occur [55]. Demethylation and
expression were observed in several different cancer cell lines, and
treatment with 5-aza-dC increased MAGE-A1 expression in
normal fibroblasts due to the demethylation in the promoter
region. Expression of MAGE-A1 and -A4 has been shown to be
correlated with disease stage in melanoma patients [23]. Both
demethylation and expression of MAGE-A1 and –A3 has been
seen in colorectal cancer [22] and in non-small cell lung cancer
patients, where expression correlated with poor prognosis [24].
Our array data indicated that two MAGE genes were demethylated by hypoxia (MAGEA11) and hypoglycaemia (MAGEB1),
though no induction in expression was observed. Nonetheless, the
MAGEs are a group of genes which support the importance of
demethylated CpG residues in transcription factor binding sites,
and that demethylation in cancer can be gene-specific.
Two other genes involved in cellular movement, AFAP1L1 and
NRAS, which were determined to be significantly upregulated in
hypoxia and hypoglycaemia by the microarrays, respectively, were
also quantified by qRT-PCR. Both of these genes did not
PLOS ONE | www.plosone.org

demonstrate increased expression when checked by qRT-PCR,
possibly due to cross-hybridization of non-specific sequences or
splice variants, two common reasons for discrepancies between
microarray findings and qRT-PCR [56].
There is sufficient evidence in the literature supporting the concept
that CpGs within different transcription factor binding sites (such as
HRE, STAT3 and ETS) must be demethylated in order for
transcription to occur, and more importantly, some of these genes
are involved in enhancing cell motility. In this study, we have
contributed to this important concept by providing evidence through
cross-platform array analysis for other cellular movement genes that
are both hypomethylated and upregulated by ischemia. We validated
changes in expression of the cellular movement genes PLAUR,
LAMB3, EPHA2,NEDD4L, andCYR61 in ischemic conditions. It is
well known that HIF1a levels are higher in breast and colon cancer
metastases [3]. This observation complements our finding that
hypoxia decreases methylation, and that a decrease in methylation in
the CpG of HREs could then facilitate HIF binding and promoter
gene expression. Perhaps hypoxia-induced decrease of DNMT levels
7
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Figure 3. Functional analysis of genes hypomethylated and upregulated by hypoxia. Ingenuity Pathways Analysis database was used to
assign genes to biological functions and determine functions that were enriched, based on statistical significance.
doi:10.1371/journal.pone.0103243.g003

IPA analysis of the cross-platform data for genes that were both
hypermethylated and downregulated identified genes involved in
cellular functions such as cellular movement and cell-to-cell
signaling and interaction (Tables II and III in Information S1).
Downregulation of genes involved in cellular adhesion could
conceptually contribute to increased cellular motility and metastasis. With further literature review, very few of these hypermethylated and downregulated genes are associated with cell-cell
adhesion. Although an interesting idea, our data does not support

is an early event in primary tumours. Cells with decreased DNA
methylation are thus then primed for transcription factor binding to
gene promoters which will enhance cellular movement, such as
PLAUR. The importance of hypoxia in cancer progression is well
demonstrated in cervical cancer patients whose tumours are hypoxic
and have increased incidence of metastasis as compared to patients
with better oxygenated tumours [57]. It is clear that hypoxia
influences cancer progression, and global changes in DNA methylation are a common occurrence influencing cancer progression [58].
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pyruvate-free DMEM. Confluent monolayers of cells were
trypsinized, and 36106 cells were plated onto 10 cm plates and
left in standard culture conditions overnight. The following day
cells were washed with PBS and switched to low serum media:
DMEM and 2% FBS. 24 hours thereafter, cells were washed with
PBS again and assigned to three groups: control, hypoxic, and
hypoglycaemic. Cells were incubated for 48 h, followed by DNA
and RNA isolation.

Microarray Preparation and Analysis
DNA and RNA were isolated from cells as described below, and
sent to the London Regional Genomics Centre, London, ON,
where samples were biotin-labeled, and all microarray hybridizations, staining, washing, scanning, and data analyses were
performed.
All microarray data have been submitted to the GEO database
(http://www.ncbi.nih.gov/geo)
under
accession
number
GSE58233.

Figure 4. Functional analysis of genes hypomethylated and
upregulated by hypoglycaemia. Ingenuity Pathways Analysis
database was used to assign genes to biological functions and
determine functions that were enriched, based on statistical significance.
doi:10.1371/journal.pone.0103243.g004

Copy Number Analysis
The Affymetrix SNP 6.0 array was used to determine genomic
integrity and detect drift/copy number variation in the HCT116
cells. Four mg of genomic DNA was Biotin-labelled, fragmented,
and hybridized to the array. This array contains probes used in
SNP analysis, as well as probes specific for CNV detection.
‘‘.CEL’’ files produced by GCOS software for each array were
then imported into Partek Genomic Suite and analyzed using the
genomic segmentation algorithm in the Copy Number Analysis
workflow using the default settings, except that both CNV and
SNP probes were used. All CEL files were background corrected
using the Robust Multichip Average Algorithm (RMA) and results
were corrected for probe GC content and fragment length.
Genetic drift and Copy Number Variation in the HCT116 cells
was determined by comparing the microarray data obtained to a
reference data set available from Affymetrix, containing 270 mixed
population samples from the International HapMap Project [29].
This array hybridization was performed in duplicate with two
independent samples.

suppression of cell-to-cell adhesion molecule expression as a likely
mechanism responsible for the increased motility seen in ischemia.
DNMT inhibitors such as decitabine have been used clinically
with some success in treating hematological malignancies such as
acute myeloid leukemia [59]. However, the efficacy of these
inhibitors has not been replicated in solid tumours [60]. Cancer
genomes undergo hypomethylation concurrently with hypermethylation [61], thus further hypomethylating with DNMT
inhibitors only resolves one half of the methylation disarray.
Additionally, solid tumours have a unique feature lacking in
hematological cancers: a microenvironment with ischemic regions.
As we have previously demonstrated, DNMT expression and
activity are reduced in ischemic conditions [28]. Therefore, using
DNMT inhibitors in tumours with ischemic regions may be
inefficient in cancer therapy if these regions are already
undergoing hypomethylation as a result of ischemia-mediated
DNMT repression.

Promoter Methylation Array
To analyze promoter methylation changes following ischemic
exposure, DNA was extracted, fragmented, and enriched for 5methylcytosine (5-mC) with the antibody-based Methylamp
Methylated DNA Capture kit. Proper fragmentation of the
DNA was confirmed following sonication by running the DNA
on an agarose gel and observing a smear from about 800 to
200 bp. The Sigma Genomeplex Complete Whole Genome
Amplification (WGA) kit was used to amplify the 5-mC enriched
DNA using the manufacturer’s instructions, except that 75 mM
dUTP was added to the reaction and number of cycles was
increased from 14 to 20. The amplified DNA was then purified
with the QiaQuick PCR purification kit. A total of 7.5 mg of the
purified 5-mC enriched DNA was then hybridized to the
Affymetrix 1.0R tiling array. Statistical parameters were set at a
significance value of p,0.01 (ANOVA) over a region of at least 10
adjacent probes, and minimum length of 400 base pairs to detect
significant/enriched regions in three biological repetitions. Enriched regions in treated samples versus control were determined
using the Model-Based analysis of Tiling arrays (MAT) algorithm
with a positive score representing a hypermethylated region, and
negative score for hypomethylated region [62]. The annotations
for the HG U133 Plus 2.0 array were used to determine which
probe sets were associated with regions appearing to be
significantly hypermethylated or hypomethylated in control versus

Conclusions
It is well known that ischemic conditions drive cancer
metastasis, and here we suggest a potential mechanism for this
common occurrence: through DNA hypomethylation facilitated
by ischemia-mediated down-regulation of DNMTs. A significant
proportion of the genes impacted by this selection pressure are
involved in cell movement. This is the first report to our
knowledge that provides an explanation for the increased
metastatic potential seen in ischemic cells; i.e. that ischemia could
be driving DNA hypomethylation and increasing expression of
cellular movement genes.

Methods
Cell Culture and Ischemia Conditions
Human colorectal cancer cells, HCT116 (obtained from the
ATCC), were cultured in DMEM supplemented with 10% fetal
bovine serum (FBS), 50 mg/ml gentamicin, and 1 mM sodium
pyruvate. Cells were grown at 37uC in a humidified chamber with
5% CO2. Hypoxic/anoxic conditions were generated using a
Modular Incubator Chamber with continuous flushing with a
humidified mixture of 95% N2 and 5% CO2. Hypoglycaemic
conditions were mimicked with the use of glucose-free and
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Figure 5. Top networks determined by Ingenuity Pathway Analysis. The top networks (most connections to central molecule) for
hypomethylated and upregulated genes are shown for both hypoxia (A) and hypoglycaemia (B). The intensity of the red colouring of the molecules
reflects the expression level as found in expression array (darker signifies greater increase in expression as compared to control conditions).
doi:10.1371/journal.pone.0103243.g005
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Figure 6. Quantitative reverse transcription-PCR to confirm expression changes in genes involved in cellular movement. cDNA levels
from HCT116 cells grown in hypoxia (A) and hypoglycaemia (B) were measured for the genes of interest and normalized to b-actin, and to control.
N = 5 for no oxygen and N = 3 for no glucose. * indicates significant difference relative to control; p#0.05.
doi:10.1371/journal.pone.0103243.g006

hybridized to the arrays. Array washing, scanning and probe
quantification were carried out as per the manufacturer’s instructions
using GCOS software, except that the target intensity was set to 150.
For each array, GCOS output was imported as ‘‘.CEL’’ files into
Partek Genomic Suite software, and data were normalized using the
RMA algorithm as above. Probe sets significantly different in no
glucose or no oxygen relative to control were determined using
ANOVA, with the nominal alpha level set to less than 0.05, and then
filtered for probe sets changing 2-fold and greater. In addition, for the
no glucose versus control the false discovery rate (FDR) was controlled
using the Benjamini and Hochberg multiple test correction. This
assay was performed in triplicate.

no oxygen and control versus no glucose, and these probe set IDs
were used in cross platform analyses. This assay was performed in
triplicate with three independent samples.

Genome-wide Expression Analysis
The Affymetrix HG U133 Plus 2.0 microarray was used to analyze
expression changes in control versus no oxygen and control versus no
glucose. Total RNA was isolated using TRIPure according to
manufacturer’s instructions. RNA integrity was verified with the
Bioanalyzer, with all samples having a RIN 9.3 or greater. 10 mg of
RNA was used to produce Biotin-labeled cRNA, which was
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Figure 7. Effect of ischemia on HCT116 invasive capabilities. Cell images taken at 106 magnification from the underside of the Matrigelcoated transwells (A). Light refractive cells (black) indicate that these cells migrated through the transwell membrane. Average number of HCT116
cells which invaded Matrigel coated transwells after 48 hours exposure to no oxygen (NO) and no glucose (NG), followed by 24 hours in the transwells
(B). * indicates significant difference from Control; p,0.01.
doi:10.1371/journal.pone.0103243.g007

Cross-Platform Analysis

Ingenuity Pathways Analysis

As per published protocols [33], Partek Software Suite was used
to overlay the promoter methylation and expression data. Probe
set IDs from the promoter and expression microarray platforms
were imported as separate lists into Partek and compared using the
Venn Analysis tool. Probe sets appearing hypomethylated and
increased in expression were compared in one analysis, and probe
sets appearing hypermethylated and decreased in expression in
another. Lists of overlapping probe sets were then generated, and
filtered in EXCEL to determine the number of unique genes
represented. Proportionate Venn diagrams were then created
based on these data sets.

The Ingenuity Pathway Analysis (IPA) database was used to
identify gene networks and canonical pathways of the genes which
were hypomethylated and upregulated. The data set containing gene
identifiers and corresponding fold changes was uploaded into the
web-delivered application and each gene identifier was mapped to its
corresponding gene object in the Ingenuity Pathways Knowledge
Base (IPKB). The functional analysis identified the biological
functions and/or diseases that were most significant to the data sets.
Fisher’s exact test was performed to calculate a P value determining
the probability that each biological function and/or disease assigned
to the data set was due to chance alone. In addition, networks were
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generated by using IPA as graphical representations of the molecular
relationships between genes and gene products. Nodes were
displayed using various shapes that represent the functional class of
gene products.

the upper portion of the transwell (Matrigel and cells) was wiped
away and the transwell rinsed again with water. Images of the
transwells were taken at 10X with an inverted microscope.
Quantification was performed by counting the number of cells in 5
fields/transwell, and invasion was expressed as the average
number of cells migrated per field.

qRT-PCR
Quantitative reverse transcription PCR was used to validate
candidate genes from the expression array. Amplification was
performed as previously described [28], with the modification of
1 mg of RNA was used for reverse transcription, and the StepOnePlus
system (Applied Biosystems) was used with PerfeCTa SYBR Green
FastMix. NRAS primer sequences were: forward 59TGTGATTTGCCAACAAGGAC-39, reverse 59-CATCTTCAACACCCTGTCTG-39. AFAP1L1 primer sequences were: forward
59-CAACCTCTCCCTGTCAACTG-39,
reverse
59TTCATTTCCCATTCCTTGGCT-39.
EPHA2,
LAMB3,
NEDD4L, CYR61, and PLAUR primers were purchased from
Qiagen; these primer sequences are proprietary. ACTB was used as a
reference gene; forward 59-AAGATCAAG ATCATTGCTCCTC39, reverse 59-CAACTAAGTCATAGTCCGCC-39. At least 3
biological replicates were used for analysis.

Statistical Analysis
Statistical tests for the microarrays are discussed separately
under their respective sections. For all other data, one-way
ANOVA was performed. If the p value was less than or equal to
0.05, then the Bonferroni correction was performed on pairs of
data. Each assay was replicated at least three times.

Supporting Information
Information S1 I. Complete list of hypomethylated and
upregulated genes by hypoglycaemia. II. Functional analysis by
IPA software of hypermethylated and downregulated genes in
hypoxia. III. Functional analysis by IPA software of hypermethylated and downregulated genes in hypoglycaemia.
(DOCX)

Invasion Assay
A transwell assay was used to assess the invasive potential of cells
in ischemia. Cells were first exposed to no oxygen or no glucose for
48 hours in 2% FBS media as described above. Transwells (inserts)
were coated with a 1:5 dilution of Matrigel (final protein
concentration of 1.55 mg/ml) in serum free DMEM, prior to
seeding 16105 ischemia-exposed cells onto the Matrigel in 0%
FBS. 10% FBS was used in the bottom wells of the plate to provide
chemoattractants. 24 hours post seeding in transwells, transwells
were removed, washed with PBS, and fixed with 4% paraformaldehdye (PFA) for 15 minutes. Transwells were then washed with
PBS and stained with 0.4% crystal violet in 10% methanol for 30
minutes. Transwells were then washed with deionized water, and
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